Speakers

Andy Holt

Chief Commercial Officer • Cellistic

Andy Holt brings more than fifteen years of experience in cell and gene therapy to Cellistic. In his prior roles, he held business development, corporate development and management positions for CDMOs, driving commercial strategy and growth in adeno-associated virus (AAV) gene therapy manufacturing. In his role at Cellistic, Andy leverages his experience in scaling up cell and gene therapy platforms to help Cellistic clients reach their goals in allogeneic cell therapy.

Also Speaking

Scott Jones

Senior Vice President & Chief Scientific Officer • BioBridge Global

Allyson Berent

Chief Science Officer • Foundation for Angelman Syndrome Therapeutics

Becky Johnson-Kent

Vice President, Europe & Women in Advanced Therapies (WiAT) Programme Lead • Phacilitate

Also Speaking

Image

2025 Downloadable Agenda

Download the post-event report for Advanced Therapies Week 2024.
Image

Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.